Transthyretin Amyloidosis (ATTR)
Transthyretin Amyloidosis (ATTR) is an underdiagnosed, rapidly progressing, fatal, multisystem disease, caused by misfolded TTR accumulating as amyloid deposits in multiple organs. Patients with ATTR amyloidosis experience progressively debilitating symptoms and high morbidity and mortality rates, making early intervention vital.
Resources
Pathology
Image
Presentation
Hereditary ATTR Amyloidosis: A Closer Look at the V122I Variant
V122I is the most common variant of hATTR amyloidosis in the United Kingdom and is most prevalent in patients of African Caribbean descent. Compared to other variants, patients with the V122I variant experience significant disease burden and poorer outcomes.
Epidemiology
Image
Presentation
Hereditary ATTR Amyloidosis: A Closer Look at the V122I Variant
V122I is the most common variant of hATTR amyloidosis in the United Kingdom and is most prevalent in patients of African Caribbean descent. Compared to other variants, patients with the V122I variant experience significant disease burden and poorer outcomes.
Diagnosis & Classification
Image
Presentation
Hereditary ATTR Amyloidosis: A Closer Look at the V122I Variant
V122I is the most common variant of hATTR amyloidosis in the United Kingdom and is most prevalent in patients of African Caribbean descent. Compared to other variants, patients with the V122I variant experience significant disease burden and poorer outcomes.
Disease Burden
Image
Presentation
Hereditary ATTR Amyloidosis: A Closer Look at the V122I Variant
V122I is the most common variant of hATTR amyloidosis in the United Kingdom and is most prevalent in patients of African Caribbean descent. Compared to other variants, patients with the V122I variant experience significant disease burden and poorer outcomes.
Therapies & Management
Image
Presentation
Hereditary ATTR Amyloidosis: A Closer Look at the V122I Variant
V122I is the most common variant of hATTR amyloidosis in the United Kingdom and is most prevalent in patients of African Caribbean descent. Compared to other variants, patients with the V122I variant experience significant disease burden and poorer outcomes.
Therapies
ONPATTRO® (patisiran)
Click below to explore a range of clinical and educational resources related to the use of patisiran in adult patients with polyneuropathy of ATTRv (also known as hATTR) amyloidosis.
AMVUTTRA® (vutrisiran)
Explore a range of clinical and educational resources related to the use of vutrisiran in adult patients with the polyneuropathy of ATTRv (also known as hATTR) amyloidosis or with the cardiomyopathy of wild type or ATTRv amyloidosis.
Congresses
Publications
Transthyretin Amyloidosis (ATTR)
Effectiveness and Utility of Genetic Testing in Establishing a Diagnosis of Hereditary Transthyretin Amyloidosis
Journal of Clinical Medicine
Transthyretin Amyloidosis (ATTR)
Impact of Patisiran on Polyneuropathy of Hereditary Transthyretin Amyloidosis in Patients with a V122I or T60A Variant: A Phase IV Multicentre Study
Annals of Medicine
Transthyretin Amyloidosis (ATTR)
Impact of Vutrisiran on Cardiac Biomarkers in Patients With Transthyretin Amyloidosis With Cardiomyopathy From HELIOS-B
Journal of the American College of Cardiology
